ClinicalTrials.gg
Active, not recruitingNCT05949593PHOENIXUpdated Jan 7, 2026

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

A Phase 3 interventional study of Tinlarebant and Placebo in Geographic Atrophy, sponsored by Belite Bio, Inc. Active, not recruiting at 49 sites in 8 countries. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Belite Bio, Inc · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
429
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
14th of 107
429 · median 98
Started
2023
with 11 others
Phase 3
15 of 131
2 open now
Primary completion
2027-06
later than 11 of 44 live
Registered
91st of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 14th largest by planned enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 15 in phase 3, reaches primary completion later than 11 of the 44 other live ones, and was the 91st registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

Read the detailed description

Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

Keywords

  • LBS-008
  • Tinlarebant
  • GA
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
  • Minimum BCVA is required in the study eye

Exclusion criteria

Exclusion Criteria:

  • The presence of diabetic macular edema or macular disease in either eye.
  • Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye.
  • Uncontrolled diagnosed glaucoma in the study eye
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
429 participants (estimated)

Study arms

  • Experimental
    LBS-008, Tinlarebant

    Drug: Tinlarebant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 5 mg tablet taken orally once a day

  • DrugPlacebo

    Placebo tablets for tinlarebant 5 mg prepared similarly.

06

What researchers measure

Primary outcomes

  1. To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size

    Time frame: From baseline to Month 24]

Secondary outcomes

  1. To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale

    Time frame: From baseline to Month 24

  2. To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT)

    Time frame: From baseline to Month 24

07

Study locations

49 sites
  • Belite Study Site
    Phoenix, Arizona 85020, United States
  • Belite Study Site
    Arcadia, California 91007, United States
  • Belite Study Site
    Beverly Hills, California 90211, United States
  • Belite Study Site
    Huntington Beach, California 92467, United States
  • Belite Study Site
    Los Angeles, California 90033, United States
  • Belite Study Site
    Palo Alto, California 94303, United States
  • Belite Study Site
    San Diego, California 92093, United States
  • Belite Study Site
    Lakeland, Florida 33805, United States
  • Belite Study Site
    Hagerstown, Maryland 21740, United States
  • Belite Study Site
    Saint Louis Park, Minnesota 55416, United States
  • Belite Study Site
    Westbury, New York 11590, United States
  • Belite Study Site
    Cary, North Carolina 27511, United States
  • Belite Study Site
    Durham, North Carolina 27710, United States
  • Belite Study Site
    Wake Forest, North Carolina 27587, United States
  • Belite Study Site
    Portland, Oregon 97239, United States
  • Belite Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Belite Study Site
    Sewickley, Pennsylvania 15143, United States
  • Belite Study Site
    Germantown, Tennessee 38138, United States
  • Belite Study Site
    Abilene, Texas 79606, United States
  • Belite Study Site
    Dallas, Texas 75231, United States
  • Belite Study Site
    San Antonio, Texas 78240, United States
  • Belite Study Site
    Warrenton, Virginia 20186, United States
  • Belite Study Site
    Chatswood, New South Wales 2067, Australia
  • Belite Study Site
    Strathfield, New South Wales 2135, Australia
  • Belite Study Site
    Brisbane, Queensland 4101, Australia
  • Belite Study Site
    Adelaide, South Australia 5000, Australia
  • Belite Study Site
    East Melbourne, Victoria 3002, Australia
  • Belite Study Site
    Crawley, Western Australia 6009, Australia
  • Belite Study Site
    Beijing, Beijing Municipality 100044, China
  • Belite Study Site
    Chengdu, Sichuan 610093, China
  • Belite Study Site
    Beijing, 10005, China
  • Belite Study Site
    Beijing, 100730, China
  • Belite Study Site
    Guandong, 510060, China
  • Belite Study Site
    Zhejiang, 325027, China
  • Belite Study Site
    Ostrava, 70852, Czechia
  • Belite Study Site
    Prague, 14000, Czechia
  • Belite Study Site
    Prague, 14059, Czechia
  • Belite Study Site
    Dijon, 21000, France
  • Belite Study Site
    Écully, 69130, France
  • Belite Study Site
    Lyon, 69317, France
  • Belite Study Site
    Marseille, 130008, France
  • Belite Study Site
    Basel, 4031, Switzerland
  • Belite Study Site
    Lausanne, 1001, Switzerland
  • Belite Study Site
    Taichung, 40447, Taiwan
  • Belite Study Site
    Taipei, 100, Taiwan
  • Belite Study Site
    Taoyuan, 33305, Taiwan
  • Belite Study Site
    Great Yarmouth, NR31 6LA, United Kingdom
  • Belite Study Site
    Harrow, HA1 3UJ, United Kingdom
  • Belite Study Site
    London, EC1V 2PD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Jul 18, 2023
StartActual
Jul 27, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949593
Lead sponsor
Belite Bio, Inc
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Jul 27, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jan 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinlarebant

Start the discussion